88 related articles for article (PubMed ID: 6413579)
21. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
[TBL] [Abstract][Full Text] [Related]
22. Isolation and characterization of a T-suppressor factor specific for the lupus-associated autoantigen RNP-Sm.
Steele JK; Levy JG; Waterfield JD
Autoimmunity; 1989; 3(1):17-28. PubMed ID: 2491618
[TBL] [Abstract][Full Text] [Related]
23. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
Rakhmilevich AL
Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
[TBL] [Abstract][Full Text] [Related]
24. The role of suppressor factors in the regulation of immune responses by ultraviolet radiation-induced suppressor T lymphocytes. III. Isolation of a suppressor factor with the B16G monoclonal antibody.
Yee GK; Levy JG; Kripke ML; Ullrich SE
Cell Immunol; 1990 Apr; 126(2):255-67. PubMed ID: 2138059
[TBL] [Abstract][Full Text] [Related]
25. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
[TBL] [Abstract][Full Text] [Related]
26. A rat monoclonal antibody that binds specifically to mouse T lymphoblasts and inhibits IL 2 receptor functions: a putative anti-IL 2 receptor antibody.
Osawa H; Diamantstein T
J Immunol; 1984 May; 132(5):2445-50. PubMed ID: 6425405
[TBL] [Abstract][Full Text] [Related]
27. Tumor growth inhibitory and natural suppressor activities of murine bone marrow cells: a comparative study.
Seledtsov VI; Taraban VY; Seledtsova GV; Samarin DM; Avdeev IV; Senyukov VV; Kozlov VA
Cell Immunol; 1997 Nov; 182(1):12-9. PubMed ID: 9427805
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a soluble factor that specifically suppresses the in vitro generation of cells cytotoxic for syngeneic tumor cells in mice.
Takei F; Levy JG; Kilburn DG
J Immunol; 1978 Apr; 120(4):1218-24. PubMed ID: 417138
[TBL] [Abstract][Full Text] [Related]
29. Stimulation of interleukin-3 dependent cell growth by specific antibody.
Kinnaird A; Garland J
Immunology; 1985 Jul; 55(3):457-61. PubMed ID: 3926635
[TBL] [Abstract][Full Text] [Related]
30. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates.
Mew D; Wat CK; Towers GH; Levy JG
J Immunol; 1983 Mar; 130(3):1473-7. PubMed ID: 6185591
[TBL] [Abstract][Full Text] [Related]
31. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
[TBL] [Abstract][Full Text] [Related]
32. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
33. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
34. Specific reversal of cytolytic T cell-target cell functional binding is induced by free target cells.
Balk SP; Mescher MF
J Immunol; 1981 Jul; 127(1):51-7. PubMed ID: 6787131
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibody against human interleukin 2 (IL 2). I. Purification of IL 2 for the production of monoclonal antibodies.
Stadler BM; Berenstein EH; Siraganian RP; Oppenheim JJ
J Immunol; 1982 Apr; 128(4):1620-4. PubMed ID: 6977565
[TBL] [Abstract][Full Text] [Related]
36. Acceptor site(s) for T cell-replacing factor (TRF) on B lymphocytes. II. Activation of B cells by cross-linkage or aggregation of the TRF acceptor molecule.
Tominaga A; Takatsu K; Hamaoka T
J Immunol; 1982 Jun; 128(6):2581-5. PubMed ID: 6978908
[TBL] [Abstract][Full Text] [Related]
37. Preparation and characterization of monoclonal antibodies reactive with porcine PBL.
Pescovitz MD; Lunney JK; Sachs DH
J Immunol; 1984 Jul; 133(1):368-75. PubMed ID: 6609988
[TBL] [Abstract][Full Text] [Related]
38. Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells.
Steele JK; Liu D; Stammers AT; Whitney S; Levy JG
Cancer Immunol Immunother; 1988; 26(2):125-31. PubMed ID: 2965972
[TBL] [Abstract][Full Text] [Related]
39. Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice.
Baradaran B; Hosseini AZ; Majidi J; Farajnia S; Barar J; Saraf ZH; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(1-2):11-6. PubMed ID: 19478394
[TBL] [Abstract][Full Text] [Related]
40. An IL 2-secreting T cell hybridoma that responds to a self class I histocompatibility antigen in the H-2D region.
Endres RO; Marrack P; Kappler JW
J Immunol; 1983 Oct; 131(4):1656-62. PubMed ID: 6604749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
